EUFLEXXA®

Bullet Point
EUFLEXXA® (1% sodium hyaluronate)
Ferring Pharmaceuticals Inc.
1% Prefilled Syringes 2mL 3/carton
Item # 27334
NDC: 55566-4100-01
HCPCS CODE: J7323
 120 Day Terms
Credit Card
Next Day Delivery
Volume pricing available

Why should you consider EUFLEXXA?
  • EUFLEXXA was shown to have 81% overall patient satisfaction in its pivotal clinical trial. 
  • Significant and sustained relief of OA knee pain at 6 months proven in the FLEXX trial. 
  • ZERO joint effusions over 1 year and proven safe with repeated injection cycles up to 1 year.*
* In the 12-week trial, there was 1 joint effusion reported in the EUFLEXXA group (n=160) vs 13 joint effusions in the Synvisc® group (n=161).
Reimbursement
Resources
EUFLEXXA (1%sodiumhyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).
 
Important Safety Information

You should not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or skin diseases or infections around the injection site.

The safety and effectiveness of EUFLEXXA has not been established in pregnant women, women who are nursing or children less than 18 years of age. After you receive this injection you may need to avoid activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).

The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.